Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Michael R Migden"'
Autor:
Dirk Schadendorf, Thomas K Eigentler, Israel Lowy, Apostolos Papachristos, Samantha Bowyer, Friedegund Meier, Brigitte Dreno, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Axel Hauschild, Brian Stein, Emmanuel Okoye, Jocelyn Booth, Matthew G Fury, Alexander Guminski, Sophie Dalac, Frank Seebach, Marie Beylot-Barry, Suk-Young Yoo, Nicole Basset-Séguin, Sabiha Trabelsi Messai, Victoria Casado Echarren, Anne J Paccaly, Jenny-Hoa Nguyen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Background Cemiplimab (Libtayo®), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are not candidates for cur
Externí odkaz:
https://doaj.org/article/85c0508e98f2481db714933c819add16
Autor:
Gregory A Daniels, Diwakar Davar, Theresa Medina, Michael R Migden, Trisha M Wise-Draper, Andrew S Poklepovic, Claire Verschraegen, Wanxing Chai-Ho, Jennifer C Tang, Praveen K Bommareddy, Shaheer A Khan, Katy K Tsai, Meenal Kheterpal, Diana Bolotin, Sherrif F Ibrahim, Nathalie C Zeitouni, Chris Tucci, Susan Navia, Laxminarasimha Donthireddy, Jeannie W Hou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/2ea6485ff7a9466d90dc9a24c998398d
Autor:
Dirk Schadendorf, Chieh-I Chen, Zhen Chen, Israel Lowy, Elizabeth Stankevich, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Brett G M Hughes, Anne Lynn S Chang, Emmanuel Okoye, Jocelyn Booth, Siyu Li, Matthew G Fury, Alexander Guminski, Medha Sasane, Alesha A Thai, Suk-Young Yoo, Vera Mastey
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background To provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL).Metho
Externí odkaz:
https://doaj.org/article/909409bad2c44f6ca8b681b154002319
Autor:
Thomas Eigentler, Danny Rischin, Michael R Migden, Annette M Lim, Chrysalyne D Schmults, Nikhil I Khushalani, Lara A Dunn, Leonel Hernandez-Aya, Anne Lynn S Chang, Badri Modi, Claas Ulrich, Brian Stein, Jessica L Geiger, Emmanuel Okoye, Melissa Mathias, Jocelyn Booth, Siyu Li, Matthew G Fury
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in a Phase 1 advanced cutaneous squamous cell carcinoma (CSCC) expansion cohort (NCT02383212) and th
Externí odkaz:
https://doaj.org/article/a6c7cd3cc4a44c238d9eeebc62a5df0f
Autor:
Carrick Burns, Shelby Kubicki, Quoc-Bao Nguyen, Nader Aboul-Fettouh, Kelly M. Wilmas, Olivia M. Chen, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden
Publikováno v:
Cancers, Vol 14, Iss 15, p 3653 (2022)
cSCC is increasing in prevalence due to increased lifespans and improvements in survival for conditions that increase the risk of cSCC. The absolute mortality of cSCC exceeds melanoma in the United States and approaches that of melanoma worldwide. Th
Externí odkaz:
https://doaj.org/article/f72e81260eeb496591a7433bee9b3b2b
Autor:
Olivia M. Chen, Keemberly Kim, Chelsea Steele, Kelly M. Wilmas, Nader Aboul-Fettouh, Carrick Burns, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden
Publikováno v:
Cancers, Vol 14, Iss 15, p 3720 (2022)
Basal cell carcinoma (BCC), the most common cancer in humans, is a malignant neoplasm of cells derived from the basal layer of the epidermis. Tumor characteristics such as histologic subtype, primary versus recurrent tumor, anatomic location, size, a
Externí odkaz:
https://doaj.org/article/11bfd3d0f3ad403d8e7533dbb66df060
Autor:
Sirunya Silapunt, Michael R. Migden, Leon Chen, Nader Aboul-Fettouh, Junsheng Ma, Jigar Patel
Publikováno v:
Australasian Journal of Dermatology. 63:36-42
PD-1 inhibitors are immunotherapeutic agents used in the treatment of advanced cutaneous squamous cell carcinoma (cSCC). This study aimed to determine the pooled objective response and disease control rates of patients with advanced cSCC treated with
Autor:
Reinhard Dummer, Aaron S. Farberg, Michael R. Migden, Alexander Guminski, Karl D. Lewis, Nicholas Squittieri
Publikováno v:
Dermatology and Therapy
Introduction Sonidegib is a Hedgehog pathway inhibitor approved to treat locally advanced basal cell carcinoma and, depending on regulatory approval, metastatic basal cell carcinoma. Results from the BOLT study demonstrated robust efficacy and contin
Publikováno v:
Clinics in Dermatology.
Dermatology is a specialty reliant on presenting detailed and accurate visual observations. Digital photography is a highly prevalent and accessible technology that can be easily incorporated into a dermatology practice to facilitate documentation an
Autor:
Amy C. Moreno, Michael K. Wong, Randal S. Weber, Priyadharsini Nagarajan, Michael R. Migden, David I. Rosenthal, Bonnie S. Glisson, Renata Ferrarotto, Neil D. Gross, Avi Benov, Anshu Khanna, Jeffrey N. Myers, Ryan P. Goepfert, Guojun Li, Sameer Kini, Frederico Omar Netto Gleber, Samantha Tam, Adel K. El-Naggar, Moran Amit, Mohamed Aashiq, Chuan Liu
Publikováno v:
European Journal of Cancer. 144:169-177
Background The last revision of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual included a specific system for cutaneous squamous cell carcinoma (CSCC) of the head and neck. Here, we assessed the prognostic performance of six cand